A Phase 4 interventional study of Everolimus and Mycophenolate mofetil + Everolimus in Cardiac Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-01-12.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study, in de novo heart transplant patients, is to evaluate whether delayed introduction of everolimus reduces the occurrence of wound healing problems, pericardial and/or pleural effusion and early acute renal insufficiency, as compared with immediate introduction of everolimus, in the firs six months after heart transplantation.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Everolimus
delayed introduction) + Cyclosporin + steroids
Drug: Mycophenolate mofetil + Everolimus
Drug pages: Mycophenolic Acid · Everolimus
Participants With at Least One Occurrence of Safety Composite Endpoint After 6 Months by Treatment Group
Comparison of 6-month cumulative incidence of safety composite endpoint (wound healing delay) related to initial transplant surgery, pleural/pericardial effusions and occurrence of acute renal insufficiency, defined as estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2, between delayed everolimus arm and immediate everolimus arm
Time frame: 6 months
Partcipants With at Least One Occurrence of Each Safety Composite Endpoint Event After 6 Months by Treatment Group
Time frame: 6 months
Hazard Cox's Model Analysis of Pericardial/Pleural Effusions
Pericardial effusions: any pericardial effusion defined as at least moderate (i.e. measuring at least 2.0 cm in diastole, in the point of largest distance between the pericardial leaflets), with or without signs of hemodynamic compromise, or leading to drainage or to prolonged hospitalization. Pleural effusions: need for surgical drainage tubes for longer than 7 days after surgery and subsequent pleural effusions leading to drainage. CI = confidence interval, HR = hazard ratio, MDRD = Modification of Diet in Renal Disease
Time frame: 6 months
Absolute and Percent Frequencies of Patients With LDL ≥ 100 mg/mL at 1, 3 and 6 Months, by Treatment Group
LDL = low density lipoprotein
Time frame: 6 months
Participants With CMV Infection and CMV Syndrome/Disease After 6 Months by Treatment Group
CMV infection is defined as pp65 antigenemia or DNAemia
Time frame: 6 months
Participants With at Least One Occurrence of Composite Treatment Failure Events
Comparison of 6-months cumulative incidence of composite treatment failure events (BPAR ≥ 2R, rejection with hemodynamic compromise, graft loss, or death) between delayed everolimus arm and immediate everolimus arm
Time frame: 6 months
| Milestone | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus |
|---|---|---|
| Started | 89 | 92 |
| Completed | 85 | 90 |
| Not completed | 4 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Administrative problem | 0 | 1 |
| Withdrew: Death | 3 | 1 |
Comparison of 6-month cumulative incidence of safety composite endpoint (wound healing delay) related to initial transplant surgery, pleural/pericardial effusions and occurrence of acute renal insufficiency, defined as estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2, between delayed everolimus arm and immediate everolimus arm
| participants | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus |
|---|---|---|
| Participants With at Least One Occurrence of Safety Composite Endpoint After 6 Months by Treatment Group | 40 (34.60 to 55.30) | 30 (23.00 to 42.20) |
| participants | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus |
|---|---|---|
| Wound healing complication | 10 (4.7 to 17.8) | 8 (2.9 to 14.50) |
| Pleural effusion | 1 (0.00 to 3.30) | 1 (0.00 to 3.20) |
| Pericardial effusion | 30 (23.90 to 43.50) | 18 (11.50 to 27.70) |
| eGFR ≤ 30 mL/min/1.73 m2 | 7 (2.30 to 13.50) | 8 (2.90 to 14.50) |
Pericardial effusions: any pericardial effusion defined as at least moderate (i.e. measuring at least 2.0 cm in diastole, in the point of largest distance between the pericardial leaflets), with or without signs of hemodynamic compromise, or leading to drainage or to prolonged hospitalization. Pleural effusions: need for surgical drainage tubes for longer than 7 days after surgery and subsequent pleural effusions leading to drainage. CI = confidence interval, HR = hazard ratio, MDRD = Modification of Diet in Renal Disease
| participants | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus |
|---|---|---|
| Hazard Cox's Model Analysis of Pericardial/Pleural Effusions | 30 | 18 |
LDL = low density lipoprotein
| participants | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus |
|---|---|---|
| Month 1 | 41 (35.70 to 56.40) | 38 (31.60 to 51.90) |
| Month 3 | 37 (32.60 to 53.50) | 37 (30.20 to 50.20) |
| Month 6 | 34 (28.10 to 48.30) | 36 (29.20 to 49.10) |
CMV infection is defined as pp65 antigenemia or DNAemia
| participants | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus |
|---|---|---|
| CMV infections | 46 (41.30 to 62.10) | 63 (59.00 to 78.00) |
| CMV syndrome/disease | 3 (0.00 to 7.10) | 6 (1.50 to 11.60) |
Comparison of 6-months cumulative incidence of composite treatment failure events (BPAR ≥ 2R, rejection with hemodynamic compromise, graft loss, or death) between delayed everolimus arm and immediate everolimus arm
| participants | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus |
|---|---|---|
| Participants With at Least One Occurrence of Composite Treatment Failure Events | 33 (27.00 to 47.10) | 26 (19.10 to 37.50) |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Immediate Introduction of Everolimus | — | 35/89 (39.3%) | 72/89 (80.9%) |
| Delayed Introduction of Everolimus | — | 31/92 (33.7%) | 68/92 (73.9%) |
| Event | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus |
|---|---|---|
| Pericardial effusionCardiac disorders | 12/89 | 4/92 |
| Transplant rejectionImmune system disorders | 7/89 | 3/92 |
| Cytomegalovirus infectionInfections and infestations | 4/89 | 6/92 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 4/89 | 1/92 |
| Wound complicationInjury, poisoning and procedural complications | 3/89 | 1/92 |
| Renal failure acuteRenal and urinary disorders | 3/89 | 1/92 |
| Cytomegalovirus syndromeInfections and infestations | 0/89 | 3/92 |
| Oedema peripheralGeneral disorders | 2/89 | 0/92 |
| Urinary tract infectionsInfections and infestations | 2/89 | 1/92 |
| Renal failureRenal and urinary disorders | 2/89 | 0/92 |
| Event | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus |
|---|---|---|
| Pericardial effusionCardiac disorders | 40/89 | 32/92 |
| Transplant rejectionImmune system disorders | 28/89 | 23/92 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 18/89 | 25/92 |
| LeukopeniaBlood and lymphatic system disorders | 16/89 | 7/92 |
| HypertensionVascular disorders | 10/89 | 11/92 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 4/89 | 10/92 |
| AnaemiaBlood and lymphatic system disorders | 9/89 | 9/92 |
| Wound complicationInjury, poisoning and procedural complications | 8/89 | 8/92 |
| Urinary tract infectionsInfections and infestations | 6/89 | 3/92 |
| PyrexiaGeneral disorders | 2/89 | 6/92 |
safety population
| Age, Continuous(years) | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus | Total |
|---|---|---|---|
| Mean | 52.69 ± 10.15 | 52.95 ± 10.19 | 52.82 ± 10.14 |
| Sex: Female, Male(Participants) | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus | Total |
|---|---|---|---|
| Female | 16 | 21 | 37 |
| Male | 73 | 71 | 144 |
| Race/Ethnicity, Customized(participants) | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus | Total |
|---|---|---|---|
| Caucasian | 88 | 88 | 176 |
| Black | 0 | 1 | 1 |
| Other | 1 | 3 | 4 |
| Weight(kilograms) | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus | Total |
|---|---|---|---|
| Mean | 74.38 ± 12.50 | 71.18 ± 12.75 | 72.76 ± 12.70 |
| Height(centimeters) | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus | Total |
|---|---|---|---|
| Mean | 170.80 ± 7.69 | 170.10 ± 8.03 | 170.44 ± 7.85 |
| Calculated BMI(kg/m2*) | Immediate Introduction of Everolimus | Delayed Introduction of Everolimus | Total |
|---|---|---|---|
| Mean | 25.44 ± 3.65 | 24.48 ± 3.33 | 24.95 ± 3.52 |
The record gives a start of Sep 2009, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mycophenolic Acid · Everolimus